Cost-effectiveness of epilepsy therapy: How should treatment effects be measured?

被引:10
作者
Langfitt, J
Wiebe, S
机构
[1] Univ Rochester, Strong Epilepsy Ctr, Rochester, NY 14642 USA
[2] Univ Western Ontario, London, ON, Canada
关键词
D O I
10.1046/j.1528-1157.43.s.4.4.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Economic evaluations aim to inform policy makers about the cost-effectiveness of different therapies so that limited health care resources may be allocated efficiently. For such evaluations, the effects of therapy must be captured by measures that are reliable. valid, and clinically meaningful, Mortality and changes in disease activity (e.g., seizure freedom, reduction in seizure frequency) may be reliable and valid, but their clinical meaning is not always apparent. Changes in widely used "quality-of-life" measures can quantify therapeutic effects, but the value of such changes to patients is not necessarily clear. This article reviews conceptual and methodological issues involved in determining the value of health effects in the context of economic evaluations of epilepsy therapies. Techniques for eliciting preferences for health effects are reviewed, The limited information on preferences for epilepsy-related health states is described. Directions for further research are suggested.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 43 条
[1]
[Anonymous], 1947, Chron World Health Organ, V1, P29
[2]
WHY SOME HEALTH POLICIES DONT MAKE SENSE AT THE BEDSIDE [J].
ASCH, DA ;
HERSHEY, JC .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (11) :846-850
[3]
Commission on outcome measurement in epilepsy, 1994-1997: Final report [J].
Baker, GA ;
Camfield, C ;
Camfield, P ;
Cramer, JA ;
Elger, CE ;
Johnson, AL ;
da Silva, AM ;
Meinardi, H ;
Munari, C ;
Perucca, E ;
Thorbecke, R .
EPILEPSIA, 1998, 39 (02) :213-231
[4]
The cost of epilepsy in the United States: An estimate from population-based clinical and survey data [J].
Begley, CE ;
Famulari, M ;
Annegers, JF ;
Lairson, DR ;
Reynolds, TF ;
Coan, S ;
Dubinsky, S ;
Newmark, ME ;
Leibson, C ;
So, EL ;
Rocca, WA .
EPILEPSIA, 2000, 41 (03) :342-351
[5]
THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[6]
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) [J].
Bialer, M ;
Johannessen, SI ;
Kupferberg, HJ ;
Levy, RH ;
Loiseau, P ;
Perucca, E .
EPILEPSY RESEARCH, 1999, 34 (01) :1-41
[7]
Deriving a preference-based single index from the UK SF-36 Health Survey [J].
Brazier, J ;
Usherwood, T ;
Harper, R ;
Thomas, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1115-1128
[8]
Brazier J., 1999, J Health Serv Res Policy, V4, P174, DOI [10.1177/135581969900400310, DOI 10.1177/135581969900400310]
[9]
DEVELOPMENT OF THE QUALITY-OF-LIFE IN EPILEPSY INVENTORY [J].
DEVINSKY, O ;
VICKREY, BG ;
CRAMER, J ;
PERRINE, K ;
HERMANN, B ;
MEADOR, K ;
HAYS, RD .
EPILEPSIA, 1995, 36 (11) :1089-1104
[10]
AN OBJECTIVE METHOD FOR THE ASSESSMENT OF PSYCHOLOGICAL AND SOCIAL-PROBLEMS AMONG EPILEPTICS [J].
DODRILL, CB ;
BATZEL, LW ;
QUEISSER, HR ;
TEMKIN, NR .
EPILEPSIA, 1980, 21 (02) :123-135